RxDoctor Payments Data

Nedra Harrington

Acute Care · Potosi, MONPI 1386805786

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.9% of the total across 360 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 43 manufacturers reported payments, led by AbbVie at 38.3% of the total. Reporting peaked in 2023 at $2,481 and has fallen 63.7% since, to $900 in 2025. Among acute care clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,140in general payments, 2019–2025

Across 360 payments — averaging $22.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$396
  • Amgen$389
  • Johnson & Johnson$316
  • Organon$277
  • Boehringer Ingelheim$260
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$8,129100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,140 in reported general payments places this provider in the 95th percentile of 272 acute care providers in Missouri.

See all acute care providers in Missouri

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide50$52,528
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$50,166
MounjaroTirzepatide24$42,395
JardianceEmpagliflozin59$41,412
FarxigaDapagliflozin Propanediol18$20,295
EliquisApixaban13$20,151
Repatha SureclickEvolocumab17$11,239
Tresiba Flextouch U-100Insulin Degludec18$10,921
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$10,665
LinzessLinaclotide15$10,529
XareltoRivaroxaban11$9,813
JanuviaSitagliptin Phosphate14$7,567
Spiriva RespimatTiotropium Bromide11$7,074
Albuterol Sulfate HfaAlbuterol Sulfate114$3,004
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$2,625

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$396$52,52850 claims
GSKTrelegy Ellipta$183$50,16647 claims
Boehringer IngelheimJardiance, Spiriva Respimat$260$48,48570 claims
Lilly USA, LLCMounjaro$245$42,39524 claims
AstraZenecaFarxiga, Breztri Aerosphere$222$30,96031 claims
PfizerEliquis$16$20,15113 claims
AbbVieLinzess, Synthroid$3,120$11,46935 claims
Johnson & JohnsonXarelto$316$9,81311 claims
MerckJanuvia$63$7,56714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 272 acute care providers in Missouri.

Other acute care in Potosi

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →